Skip to main content
Premium Trial:

Request an Annual Quote

More Booster Discussions

Both Moderna and Johnson & Johnson say their data supports boosters for their SARS-CoV-2 vaccines, NPR says.

It notes that advisors to the US Food and Drug Administration are meeting later this week to discuss the possibility of boosters for those companies' vaccines. Last month, the agency authorized a booster dose of Pfizer and BioNTech's SARS-CoV-2 vaccine for individuals 65 years old and older and for younger individuals at increased risk of contracting COVID-19 due to underlying medical conditions or exposure at their jobs.

In documents released ahead of the meetings, Moderna says that its immune and side effect data supports a booster — its booster is a 50 microgram dose, as compared to the 100 microgram initial doses — among adults six months after their initial inoculation, NPR reports, noting that the company also cited the Delta variant in the need for a booster. Likewise, J&J says its data supports a booster six months after the initial shot, or as soon as two months for high-risk individuals, it adds.

The AP notes that the discussions for the Moderna and Johnson & Johnson boosters will be more complicated than those for the Pfizer-BioNTech booster, as the panel has to weigh the different dose for the Moderna booster and the timing of the J&J booster.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.